EXEL Exelixis Inc.

21.14
+0.4  (+2%)
Previous Close 20.74
Open 20.79
Price To Book 4.61
Market Cap 6,379,361,906
Shares 301,767,356
Volume 2,123,966
Short Ratio
Av. Daily Volume 3,148,924

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data did not meet primary endpoint - June 20, 2019.
IMspire170 - cobimetinib and atezolizumab
First-line BRAF wild-type metastatic or unresectable locally advanced melanoma
Phase 3 data released May 10, 2018. Primary endpoint not met.
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 2 ongoing.
CABOMETYX (cabozantinib)
Recurrent endometrial cancer
Phase 3 data due early 2020.
CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER
First-line renal cell carcinoma
Approved November 29, 2012.
Cabozantinib
Medullary thyroid cancer
Phase 3 trial met primary endpoint - September 24, 2017. Japanese regulatory filing due 1Q 2018.
Esaxerenone (CS-3150)
Essential hypertension
Late breaker at ESMO September 10, 2017 showed PFS 8.6 months versus 5.3 months for sunitinib. HR 0.48. PDUFA date under priority review for sNDA February 15, 2018. Approval announced December 19, 2017.
Cabozantinib - CABOSUN
First-Line RCC - cancer
FDA Approval announced January 14, 2019.
Cabozantinib (CELESTIAL)
Advanced hepatocellular cancer (HCC)
Approved April 25 2016.
CABOMETYX (cabozantinib)
Metastatic renal cell cancer (RCC)
Approved November 10, 2015.
Vemurafenib
BRAF V600 Mutation-Positive Advanced Melanoma - Cancer
Phase 3 COMET-2 trial did not meet endpoint December 1 2014
Cabozantinib
Cancer - Castration-Resistant Prostate Cancer
Phase 3 trial initiation announced October 8, 2018.
Cabozantinib
Thyroid Carcinoma
Phase 3 data due 2019.
IMspire150 - cobimetinib, atezolizumab and vemurafenib - TRILOGY
BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma
Phase 1b trial expansion announced June 1, 2018.
Cabozantinib + atezolizumab (TECENTRIQ) COSMIC-021
Solid tumors
Phase 3 initiation announced December 5, 2018.
CABOMETYX (cabozantinib) + atezolizumab (TECENTRIQ) - (COSMIC-312)
Hepatocellular Carcinoma
Phase 1 trial initiation announced February 12, 2019.
XL092
Solid tumors
Phase 3 trial initiation announced May 1, 2019.
Cabozantinib and Nivolumab and Ipilimumab (COSMIC-313)
Renal Cell Carcinoma

Latest News

  1. Health Care Digest: How California's stem cell institute may help find glaucoma cure; a stealthy biotech with $100M; and more
  2. Read This Before You Buy Any New Cancer Drug Stocks
  3. Oh, By the Way, This Clinical Trial Didn't Work
  4. Exelixis Stock Is Up despite Disappointing Clinical Trial Results
  5. Dow Jones Futures: Canopy Growth, PayPal, Lululemon, Exelixis Active
  6. The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy
  7. Here’s What Hedge Funds Think About Exelixis, Inc. (EXEL)
  8. 2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land
  9. See what the IHS Markit Score report has to say about Exelixis Inc.
  10. Exelixis Bets on Breakthroughs in Oncology
  11. Top 5 Stocks in the Fight Against Cancer
  12. Why Is Exelixis (EXEL) Down 1% Since Last Earnings Report?
  13. Is Exelixis, Inc.'s (NASDAQ:EXEL) CEO Being Overpaid?
  14. Exelixis Announces Webcasts of Investor Conference Presentations in June 2019
  15. Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics
  16. Merck to Buy Private Cancer Drugmaker Peloton Therapeutics
  17. Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program
  18. Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer
  19. Exelixis Announces Webcasts of Investor Conference Presentations on May 21, 2019